CCIA
FULC icon

Campbell & Co Investment Adviser’s Fulcrum Therapeutics FULC Stock Holding History

Campbell & Co Investment Adviser’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,601
Closed -$403K – 1184
2025
Q4 		$403K Sell
35,601
-66,869
-65% -$680K 0.02% 899
2025
Q3 		$943K Buy
+102,470
New +$741K 0.07% 439

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Campbell & Co Investment Adviser's FULC Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 35,601 shares — an estimated $403K sold.

Campbell & Co Investment Adviser first reported a position in FULC in Q3 2025 and held it in 2 quarters. The position peaked at $943K in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 35,601 Fulcrum Therapeutics shares in Q1 2026, an estimated $403K.
  • Campbell & Co Investment Adviser first reported a position in Fulcrum Therapeutics in Q3 2025 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Fulcrum Therapeutics position peaked at $943K in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.